3Weiss RB, Donchower RC, Wiemik PH, et al. Hypersensitivity reaction from taxol [J]. J Clin Oncol, 1990;8(7): 1263 - 1268
4Olson JK, Sood AK, Sorosky JI, et al. Taxol hypersensitivity: rapid retreatment is safe and cost effecitive [J]. J Gynecol oncol, 1998; 68 (1):25-28
5Hanauske AR, Degen D, Hilsenbeck SG, et al. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs, 1992, 3:121-124.
6Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol, 1992, 30:444-450.
7Figgitt DP, Wiseman LR. Docetaxel: an update of its use in advanced breast cancer. Drugs, 2000, 59:621-651.
8Sparano JA. Taxanes for breast cancer: an evidence-based review of randomized phase Ⅱ and phase Ⅲ trials. Clin Breast Cancer, 2000,1 : 32-40.
9Fulton B, Spencer CM. Docetaxel : a review of its pharmaeodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs, 1996, 51 : 1075-1092.
10Kruijtzer CMF, Verweij J, Schellens JH, et al. Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands. Anticancer Drugs, 2000, 11:249-255.
